OSI Gains US Marketing Rights for Gelclair™ from Celgene
By Business Review Editor
PharmaDeals Review: Vol 2003 Issue 38 (Table of Contents)
Published: 3 Jul-2003
DOI: 10.3833/pdr.v2003i38.889 ISSN: 1756-7874
Section: Distribution & Marketing
Abstract
OSI Pharmaceuticals has recovered US marketing rights to Gelclair™ for oncology indications from Celgene...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login on the top right purple box.
Copyright: PharmaVentures Ltd
Last Issue PDF
RSS